US · Healthcare · Biotechnology
EPS came in at -0.81 against a street estimate of -1.01 — a beat of 19.8%.
Analysts rate Viridian Therapeutics Inc a strong buy (17 buy, 0 hold, 0 sell out of 17) with an average price target of $36.20.
| Fund | Stake |
|---|---|
| FMR Inc | 14.66% |
| BlackRock Inc | 7.55% |
| Bellevue Group AG | 5.94% |
| Paradigm Biocapital Advisors LP | 5.93% |
| Kynam Capital Management, LP | 5.70% |
| State Street Corp | 5.41% |
| T. Rowe Price Associates, Inc. | 5.07% |
| Fairmount Funds Management LLC | 4.49% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the three months ended September 30, 2026, total revenue was $25,752 thousand, including $24,671 thousand of product revenue. | 2026-11-04 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Lumvoa generated $24.7 million in net product revenue in Q3 2026, versus no product revenue in Q3 2025. • More than 100 patients | 2026-11-04 |
| Quarterly report · Q2 2026 VIRIDIAN THERAPEUTICS, INC. — FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and marketable securities: $981.5 million a | 2026-08-06 |
| Results announced · Q3 2026 VIRIDIAN THERAPEUTICS Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Cash Position: $981.5 million in cash, cash equivalents, and marketable securitie | 2026-08-06 |
| Reg FD disclosure · Q2 2026 VIRIDIAN THERAPEUTICS, INC. — 8-K SUMMARY HEADLINE NUMBERS • FDA approved Lumvoa™ (veligrotug-vvze) on June 26, 2026 for treatment of thyroid eye di | 2026-06-29 |
| Shareholder vote results · Q2 2026 VIRIDIAN THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Common shares outstanding as of April 7, 2026 (record date): 103,071,889 shares • Annua | 2026-06-03 |
| Current report · Q2 2026 VIRIDIAN THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company completed voluntary full prepayment of debt on May 27, 2026 • Total payoff amou | 2026-05-28 |
| Quarterly report · Q1 2026 VIRIDIAN THERAPEUTICS, INC. - Q1 2026 SUMMARY HEADLINE NUMBERS • Net loss Q1 2026: $104.9 million (vs. $86.9 million Q1 2025) • Net loss per share: | 2026-05-05 |
Readable in the app.
| Announcement | Date |
|---|---|
| Manufacturing services agreement entered into with WuXi Biologics Viridian Therapeutics signed a manufacturing agreement with WuXi Biologics on May 24, 2026, to produce its drug candidate veligrotug for commercial sale if approved. Under the 5-year agreeme | 2026-05-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Viridian Therapeutics Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.